WVE - Wave Life Sciences Ltd.
IEX Last Trade
5.74
0.030 0.523%
Share volume: 377,974
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$5.71
0.03
0.53%
Fundamental analysis
32%
Profitability
35%
Dept financing
50%
Liquidity
75%
Performance
15%
Performance
5 Days
0 0%
1 Month
-12.50%
3 Months
-6.97%
6 Months
12.55%
1 Year
28.13%
2 Year
102.83%
Key data
Stock price
$5.74
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.50 - $7.67
52 WEEK CHANGE
$0.26
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Paul Bolno
Region: US
Website: https://www.wavelifesciences.com/
Employees: 298
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.wavelifesciences.com/
Employees: 298
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
Recent news